The FAERS Public Dashboard and its Value to the Pharmaceutical Industry
Jul 31, 2018 - 00:24:45
Radio and PodcastLive Radio & PodcastsHealth
FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer
FDA medical oncologists discuss the agency’s accelerated approval of rucaparib for treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer who have been treated with two or more chemothera...
About This Episode
FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer is an episode from FDA Drug Information Updates by ReachMD. FDA medical oncologists discuss the agency’s accelerated approval of rucaparib for treatment of patients with deleterious BRCA mutation-...
Podcast
This episode belongs to FDA Drug Information Updates.
Listen Online
Use the player on this page to stream the episode online.
Episode Details
Published May 17, 2017, 00:05:00 long, audio available.
Related Episodes
Continue listening to more episodes from FDA Drug Information Updates.
FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)
May 4, 2018 - 00:02:59
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
Jan 7, 2018 - 00:08:29
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
Jan 5, 2018 - 00:02:59
The FDA's Adverse Event Reporting System (FAERS) Public Dashboard
Oct 29, 2017 - 00:09:22
FDA D.I.S.C.O.: L-Glutamine for Sickle Cell Disease
Aug 17, 2017 - 00:05:29
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
Jul 28, 2017 - 00:06:00